Stockscreener 앱 받기
9.50
28.62%
-3.77
시간 외 거래:
9.75
0.25
+2.63%
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decline in Short Interest - Defense World
Artelo Biosciences IncRegains Nasdaq Minimum Bid Price Compliance - MarketScreener
Artelo Biosciences (NASDAQ:ARTL) Stock Rating Lowered by D Boral Capital - Defense World
Trading Halted for Artelo Biosciences (ARTL) as Investors Await News | ARTL Stock News - GuruFocus
Artelo Biosciences Engineers Reverse Stock Split - mg Magazine
# Artelo Biosciences announces 6-for-1 reverse stock split By Investing.com - Investing.com South Africa
# Artelo Biosciences announces 6-for-1 reverse stock split - Investing.com Australia
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital - GuruFocus
Artelo Biosciences stock rating cut to Hold by D. Boral Capital - Investing.com Canada
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital | ARTL Stock News - GuruFocus
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Artelo Biosciences to Implement 6-for-1 Reverse Stock Split; Shares Down - marketscreener.com
Artelo Biosciences (ARTL) Downgraded to Hold Following Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences, Inc. Announces 6-for-1 Reverse Stock Split to Comply with Nasdaq Listing Requirements - Nasdaq
Artelo Biosciences Announces Reverse Stock Split - The Manila Times
Artelo Sets 6-for-1 Reverse Split for June 13: Key Details on Share Consolidation Plan - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Receives Continued 'Buy' Rating from D. Boral Capital | ARTL Stock News - GuruFocus
Artelo Biosciences presents promising OA pain treatment data By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) Highlights New FABP Inhibitor Data at British Pain Conference | ARTL Stock News - GuruFocus
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - The Manila Times
Artelo Biosciences presents promising OA pain treatment data - Investing.com
Non-Opioid Pain Drug Shows Breakthrough Results: Matches Popular Painkiller Naproxen in Major Study - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell? - Defense World
ARTL: Potential of Fabp Inhibitors in Treating Mood Disorders Hi - GuruFocus
Independent Study Confirms Breakthrough Potential of Artelo's Novel Anxiety DrugPhase 1 Data Coming - Stock Titan
Artelo Biosciences Reports Q1 2025 Financial Results - TipRanks
Artelo Biosciences Faces Nasdaq Compliance Challenge - TipRanks
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com
Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus
Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times
Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq
Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
0.27%
0.50%
자본화:
|
볼륨(24시간):